YZR

YZR

YZR was co-founded by Prof. Dr. Reinhard Meier, a practicing physician turned tech investor, and Markus Feuerecker, who spent his career scaling healthcare companies across venture, growth, and buyout stages. The firm roots itself in the conviction that Europe's deep talent pool and rising digital health adoption create an opening for a specialist fund led by operators who have worked inside both hospitals and investment committees. YZR writes initial checks at pre-Seed and Seed, leads rounds through Series A, and participates selectively in Series B follow-ons. Its portfolio spans AI-driven diagnostics, virtual care, and digital health platforms. Confirmed positions include Scan.com, a medical imaging marketplace ranked second among healthtech startups by The Sunday Times 100 Tech (2026) and a top-10 Sifted 250 entrant; Biorce, which raised $52 million to accelerate AI-powered clinical trials; and Doctor.One, which secured €4 million for an asynchronous chronic care platform. Other disclosed investments include roclub, a medtech staffing platform that landed $11.7 million, and dehaze, an AI chronic disease detection company that raised €3.2 million. Geographically, the firm invests across Germany, France, the UK, Spain, Italy, CEE, and the Nordics, positioning itself as a pan-European specialist rather than a single-country fund. The firm operates with a lean, specialist team that includes physicians, scientists, and former Bain & Company and GP Bullhound investment banking professionals. Advisory board members include Dr. Michael Bitzer, the former CEO of UAE insurer Daman, and Elmar Willebrand, the former Group CEO of Asklepios Clinics. YZR does not publicly disclose total AUM or aggregate deployment figures. Its website references "Fund KPIs" and disciplined deployment aligned with a long-term vision but provides no quantified commitments or fund size. YZR is structurally distinct as a founder-led, operator-trained platform rather than a spinout from a larger asset manager or a family office. Its founding thesis — to fill a knowledge gap in European HealthTech by combining medical training with institutional investment rigor — means its investment committee is staffed by people who have treated patients and run hospital systems, not just managed LP capital. This clinical governance layer is rare among early-stage European VCs and anchors the firm's strategy of leading rounds and providing regulatory, hiring, and international expansion support to portfolio companies.